SPN-820 was well-tolerated with few adverse events. Earlier this month, the FDA approved Supernus Pharmaceuticals’ ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830 ...

Earlier this month, the U.S. Food and Drug Administration approved Supernus' drug-device combination, Onapgo, to treat movement-related symptoms of Parkinson's disease. The company makes ...

Earlier this month, the FDA approved ONAPGO Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with ...

Reports Q4 revenue $174.2M, consensus $155.25M. “Our 2024 results reflect solid commercial execution across the company, including continued ...

About Supernus Pharmaceuticals ... to commercialize its products and the products of its subsidiaries including ONAPGO; the Company’s ability to enter into future collaborations with ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset missed its primary endpoint in a phase 2b trial. SPN-820 failed to improve ...

Fourth quarter 2024 net sales of Qelbree ® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 millio ...

Earlier this month, the FDA approved ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with ...

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced ...